600276 恒瑞医药
2026/06 - 中期
人民币(K¥)
2025/12
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
经营活动产生之现金流量净额1,987,00411,235,3787,422,7537,643,6651,265,265
投资活动产生之现金流量净额(1,824,598)(2,740,502)(1,911,986)1,222,315390,289
筹资活动产生之现金流量净额(1,589,787)7,781,707(1,550,590)(3,144,426)(318,770)
汇率变动对现金及现金等价物的影响(696,647)(360,133)7,40112,53380,497
现金及现金等价物净增加/(减少)(2,124,028)15,916,4513,967,5785,734,0871,417,281
期初现金及现金等价物余额40,155,55324,239,10220,271,52414,537,43713,120,156
期末现金及现金等价物余额38,031,52540,155,55324,239,10220,271,52414,537,437